NICE

NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold

NICE Recommends AstraZeneca's Imfinzi for PD-L1-Positive NSCLC

NICE Recommends Merck's Tepmetko for NSCLC Patients With METex14 Skipping Mutation

NICE Recommends Against Piqray Combo for PIK3CA-Mutated Metastatic Breast Cancer

NHS England Expediting Access to Takeda's Exkivity for Certain NSCLC Patients

UK's NICE Recommends Against Merck's Keytruda, Chemo Combo for Advanced PD-L1-Positive TNBC

NICE Recommends Seagen's Tukysa for Advanced HER2-Positive Breast Cancer in England

NICE Backs AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC Through Cancer Drugs Fund

NICE Recommends Eli Lilly's Retsevmo for RET-Altered NSCLC Through Cancer Drugs Fund

UK's NICE Gives Negative Guidance on Seagen's Tukysa Combo in HER2-positive Advanced Breast Cancer

UK's NICE Recommends Selpercatinib for RET-Altered Thyroid Cancers Through Cancer Drugs Fund

UK's NICE Recommends Roche's Tecentriq for First-Line PD-L1-Positive Bladder Cancer

UK's NICE Supports Keytruda With Chemo for PD-L1 Positive Esophageal Cancer Patients

UK's MHRA Grants Early Access to Amgen's Lumakras for KRAS-Mutant Lung Cancer

NICE Recommends Incyte's Pemazyre for FGFR2-Positive Bile Duct Cancer

UK's NICE Recommends Approval of Opdivo, Yervoy for MSI-High, MMR-Deficient Colorectal Cancer

NICE Recommends Keytruda for Metastatic MSI-High, Mismatch Repair-Deficient Colorectal Cancer

UK's MHRA Grants Early Access to AstraZeneca's Tagrisso as Adjuvant NSCLC Treatment

NICE Recommends Enhertu for Advanced HER2-Positive Breast Cancer Through Cancer Drugs Fund

NICE Recommends Lynparza, Avastin Combination in Ovarian Cancer Through Cancer Drugs Fund